Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19
Shots:
- The P-III trial involves assessing REGEN-COV (casirivimab & imdevimab- 1200/2400mg- IV) vs PBO in non-hospitalized patients with COVID-19
- The trial met its 1EPs i.e. showed a reduction in the risk of hospitalization and death with both doses by 70% /71% respectively and met its 2EPs including the ability to reduce symptom duration. The P-II trial showed viral reductions for all REGEN-COV doses tested- including as low as 300 mg
- Additionally- Regeneron will share new data with regulatory authorities immediately and request that a lower 1-200 mg dose be added to EUA
Ref: Regeneron | Image: WRGB
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com